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Methods. Culture positive M. tuberculosis cases were identified from microbiological database. Clinical and laboratory data were retrieved retrospectively from January 1, 2010 to December 31, 2012. Logistic regression was performed to determine associated factors of infection with drug-resistant M. tuberculosis.
Results. A total of 758 patients were identified with median (interquartile range) age was 47 (32-64) years and 55% were males. Of all, 71.8% had pulmonary involvement. Extrapulmonary involvement was lymph node (14.9%), bone and joint (4.2%), pleura (3%), blood (2.4%) and central nervous system (1.6%). HIV infection was identified in 10.6%. Patients with HIV infection were younger (36 vs 49 years, p <0.001), had higher proportion of males (76.2% vs 53.1%, p <0.001) and smoking (60% vs 33.4%, p <0.001), lower proportion of positive sputum culture (53.8% vs 73.9%, p <0.001), and having favorable outcomes (cure or complete treatment) (33.8% vs 61.7%, p <0.001). Resistance to any first-line drugs were 18.2%; isoniazid 12.7%, rifampicin 2.1%, ethambutal 2.5%, and streptomycin 8.2%. Prevalence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) were 1.3% and 0.4%, respectively. By multivariate logistic regression, chronic cough [odds ratio (OR) 1.71; 95% confidence interval (CI) 1.17-2.49, p = 0.005] and had a history of contact person with TB (OR 2.38; 95% CI 1.32-4.28, p = 0.004) were associated with any first-line drug resistance. Of all, 58.7% patients had favorable outcomes. Female (OR 1.59; 95% CI 1.16-2.18, p = 0.004), weight at TB diagnosis (OR 1.02; 95% CI 1.00-1.03, p = 0.025), and HIV infection (OR 0.36, p <0.001) were associated with favorable outcome.
Conclusion. We demonstrate high prevalence of any first-line drug resistance, but low prevalence of both MDR-TB and XDR-TB in Thailand. Only approximately 60% patients had favorable outcomes. HIV screening in patients with TB was important for identifying patients with unfavorable outcome.
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